Literature DB >> 23179937

High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma.

Yan-Feng Chen1, Rong-Zhen Luo, Yong Li, Bo-Kang Cui, Ming Song, An-Kui Yang, Wen-Kuan Chen.   

Abstract

In order to provide a basis for clinical treatment decisions, we explored whether there was a correlation between the expression of COX-2 and P300 and clinical factors in a group of patients with laryngeal squamous cell carcinoma (LSCC). A retrospective analysis of clinicopathological data was conducted in 80 patients with LSCC who presented between January 1997 and December 1998. An immunohistochemistry tissue microarray was conducted of 80 surgically resected LSCC and 20 adjacent normal tissue specimens. Survival analysis and Kaplan-Meier curves were used to compare the effects of clinicopathological factors on survival. The Cox model was applied for multivariate analysis. The expression level of COX-2/P300 in LSCC tissues and adjacent normal tissues were 47.5/50.0 versus 0.0/15.0 %. The expression of COX-2 and P300 was correlated with higher T category, N category, clinical staging, histological grade and recurrence (P < 0.05). P300 expression was correlated with COX-2 expression (P < 0.05). Univariate survival analysis showed that P300, COX-2, N category, clinical staging and recurrence factors were closely correlated with unfavorable survival (P < 0.05). Multivariate analysis showed that COX-2 expression, histological grade and recurrence were independent prognostic factors for LSCC. High expression levels of COX-2 and P300 indicated poor survival outcomes for patients with LSCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179937      PMCID: PMC3580132          DOI: 10.1007/s00405-012-2275-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  30 in total

1.  Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes.

Authors:  Byeong-Woo Park; Seho Park; Hyung Seok Park; Ja Seung Koo; Woo Ick Yang; Jun Sang Lee; Hyewon Hwang; Seung Il Kim; Kyong Sik Lee
Journal:  Breast Cancer Res Treat       Date:  2012-06       Impact factor: 4.872

2.  Cyclooxygenase-2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma.

Authors:  Yoshihiro Morita; Kenji Hata; Masako Nakanishi; Toshihiko Nishisho; Yoshiaki Yura; Toshiyuki Yoneda
Journal:  Int J Oncol       Date:  2012-06-25       Impact factor: 5.650

3.  Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells.

Authors:  Jingshu Wang; Xiangsheng Xiao; Yun Zhang; Dingbo Shi; Wangbing Chen; Lingyi Fu; Liqun Liu; Fangyun Xie; Tiebang Kang; Wenlin Huang; Wuguo Deng
Journal:  J Pineal Res       Date:  2012-02-16       Impact factor: 13.007

Review 4.  The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease.

Authors:  R Janknecht
Journal:  Histol Histopathol       Date:  2002-04       Impact factor: 2.303

5.  COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway.

Authors:  Yan-Hong Wang; Ming-Wei Wu; An-Kui Yang; Wei-Dong Zhang; Jian Sun; Tian-Run Liu; Yan-Feng Chen
Journal:  Med Oncol       Date:  2010-11-11       Impact factor: 3.064

6.  Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression.

Authors:  Supriya Shah; Shikha Prasad; Karen E Knudsen
Journal:  Cancer Res       Date:  2012-01-18       Impact factor: 12.701

7.  High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma.

Authors:  Yong Li; Hao-Xian Yang; Rong-Zhen Luo; Ying Zhang; Mei Li; Xin Wang; Wei-Hua Jia
Journal:  Ann Thorac Surg       Date:  2011-05       Impact factor: 4.330

8.  High expression of p300 is linked to aggressive features and poor prognosis of nasopharyngeal carcinoma.

Authors:  Zhi-Wei Liao; Tong-Chong Zhou; Xiao-Jun Tan; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Wen-Jin Huang; Li-Li Du; Bo-Jun Tu; Xiao-Dan Lin
Journal:  J Transl Med       Date:  2012-05-30       Impact factor: 5.531

9.  Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling.

Authors:  Xiangsheng Xiao; Dingbo Shi; Liqun Liu; Jingshu Wang; Xiaoming Xie; Tiebang Kang; Wuguo Deng
Journal:  PLoS One       Date:  2011-08-08       Impact factor: 3.240

10.  A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.

Authors:  Stefanie Meyer; Thomas J Fuchs; Anja K Bosserhoff; Ferdinand Hofstädter; Armin Pauer; Volker Roth; Joachim M Buhmann; Ingrid Moll; Nikos Anagnostou; Johanna M Brandner; Kristian Ikenberg; Holger Moch; Michael Landthaler; Thomas Vogt; Peter J Wild
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

View more
  18 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

2.  Prognostic role of upregulated P300 expression in human cancers: A clinical study of synovial sarcoma and a meta-analysis.

Authors:  Zihan Liu; Yonglai He; Xiaojuan Lian; Hong Zou; Yalan Huang; Ning Wang; Jianming Hu; Xiaobin Cui; Jin Zhao; Wenjie Zhang; Wenyi Gu; Lijuan Pang; Yan Qi
Journal:  Exp Ther Med       Date:  2019-08-16       Impact factor: 2.447

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.

Authors:  Bo Ram Kim; Etienne Coyaud; Estelle M N Laurent; Jonathan St-Germain; Emily Van de Laar; Ming-Sound Tsao; Brian Raught; Nadeem Moghal
Journal:  Mol Cell Proteomics       Date:  2017-08-09       Impact factor: 5.911

5.  Prognostic and Clinical Significance of COX-2 Overexpression in Laryngeal Cancer: A Meta-Analysis.

Authors:  Jingwei Du; Jun Feng; Deyan Luo; Lijuan Peng
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

Review 6.  Histone Modifications and Cancer.

Authors:  James E Audia; Robert M Campbell
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-04-01       Impact factor: 10.005

7.  MicroRNA-892a regulates laryngocarcinoma cell proliferation via Dicer.

Authors:  Jinhui Dong; Jianxing Wang; Chunguang Shan; Haizhong Zhang; Ou Xu
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-14

Review 8.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

9.  Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells.

Authors:  Jingshu Wang; Liqun Liu; Huijuan Qiu; Xiaohong Zhang; Wei Guo; Wangbing Chen; Yun Tian; Lingyi Fu; Dingbo Shi; Jianding Cheng; Wenlin Huang; Wuguo Deng
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

10.  Expression of selected regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer and their clinical significance.

Authors:  Janusz Klatka; Ewelina Grywalska; Maria Klatka; Magdalena Wasiak; Adrian Andrzejczak; Jacek Rolinski
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-30       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.